These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

379 related items for PubMed ID: 30507740

  • 1. Subclinical Antibody-mediated Rejection After Kidney Transplantation: Treatment Outcomes.
    Parajuli S, Joachim E, Alagusundaramoorthy S, Blazel J, Aziz F, Garg N, Muth B, Mohamed M, Mandelbrot D, Zhong W, Djamali A.
    Transplantation; 2019 Aug; 103(8):1722-1729. PubMed ID: 30507740
    [Abstract] [Full Text] [Related]

  • 2. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
    Zheng J, Xue W, Qing X, Jing X, Hou J, Tian X, Guo Q, He X, Cai J.
    Clin Transpl; 2014 Aug; ():223-30. PubMed ID: 26281149
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Durable renal response after combination of bortezomib, corticosteroids, rituximab, and plasmapheresis for late antibody-mediated renal transplant rejection
.
    Ding Y, Francis J, Gautam A, Pelletier L, Sanchorawala V, Quillen K.
    Clin Nephrol; 2018 Apr; 89(4):252-259. PubMed ID: 29208204
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Impact of active antibody-mediated rejection treatment on donor-specific antibodies in pediatric kidney transplant recipients.
    Kincaide E, Hitchman K, Hall R, Yamaguchi I, Ding Y, Crowther B.
    Pediatr Transplant; 2019 Dec; 23(8):e13590. PubMed ID: 31617318
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Mid-Term Outcomes After Treatment for Antibody-Mediated Rejection by De Novo Donor-Specific HLA Antibody in Renal Transplant Recipients: Does Early Treatment Lead to Better Outcomes?
    Okada M, Tomosugi T, Futamura K, Hiramitsu T, Goto N, Narumi S, Takeda A, Watarai Y.
    Transplant Proc; 2020 Dec; 52(10):3051-3057. PubMed ID: 32694058
    [Abstract] [Full Text] [Related]

  • 10. Outcome of Desensitization Therapy in Immunologically High-Risk Kidney Transplantation: Single-Center Experience.
    Sinangil A, Ucar ZA, Koc Y, Barlas S, Abouzahir S, Ecder ST, Akin EB.
    Transplant Proc; 2019 Sep; 51(7):2268-2273. PubMed ID: 31358450
    [Abstract] [Full Text] [Related]

  • 11. Failure to remove de novo donor-specific HLA antibodies is influenced by antibody properties and identifies kidney recipients with late antibody-mediated rejection destined to graft loss - a retrospective study.
    Cioni M, Nocera A, Tagliamacco A, Basso S, Innocente A, Fontana I, Magnasco A, Trivelli A, Klersy C, Gurrado A, Ramondetta M, Boghen S, Catenacci L, Verrina E, Garibotto G, Ghiggeri GM, Cardillo M, Ginevri F, Comoli P.
    Transpl Int; 2019 Jan; 32(1):38-48. PubMed ID: 30076765
    [Abstract] [Full Text] [Related]

  • 12. Clinical Significance of Microvascular Inflammation in the Absence of Anti-HLA DSA in Kidney Transplantation.
    Parajuli S, Redfield RR, Garg N, Aziz F, Mohamed M, Astor BC, Zhong W, Djamali A, Mandelbrot DA.
    Transplantation; 2019 Jul; 103(7):1468-1476. PubMed ID: 30335696
    [Abstract] [Full Text] [Related]

  • 13. Clearance of Intra-graft Donor Specific Anti-HLA Antibodies in the Early Stage of Antibody-Mediated Rejection Following Rituximab and Apheresis Therapy in Renal Transplantation.
    Nakamura T, Yoshimura N, Akioka K, Shirouzu T, Kawai S, Imanishi Y, Matsuyama T, Harada S, Nobori S, Ushigome H.
    Transplant Proc; 2019 Jun; 51(5):1365-1370. PubMed ID: 31056246
    [Abstract] [Full Text] [Related]

  • 14. Long-term results of desensitization protocol with and without rituximab in sensitized kidney transplant recipients.
    Green H, Nesher E, Aizner S, Israeli M, Klein T, Zakai H, Rahamimov R, Rozen-Zvi B, Mor E.
    Clin Transplant; 2019 Jun; 33(6):e13562. PubMed ID: 30941818
    [Abstract] [Full Text] [Related]

  • 15. Outcomes of Prolonged Treatment With Intravenous Immunoglobulin Infusions for Acute Antibody-mediated Rejection in Kidney Transplant Recipients.
    Bujnowska A, Michon M, Konopelski P, Hryniewiecka E, Jalbrzykowska A, Perkowska-Ptasinska A, Cieciura T, Zagozdzon R, Paczek L, Ciszek M.
    Transplant Proc; 2018 Jun; 50(6):1720-1725. PubMed ID: 29961551
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Quantifying renal allograft loss following early antibody-mediated rejection.
    Orandi BJ, Chow EH, Hsu A, Gupta N, Van Arendonk KJ, Garonzik-Wang JM, Montgomery JR, Wickliffe C, Lonze BE, Bagnasco SM, Alachkar N, Kraus ES, Jackson AM, Montgomery RA, Segev DL.
    Am J Transplant; 2015 Feb; 15(2):489-98. PubMed ID: 25611786
    [Abstract] [Full Text] [Related]

  • 20. Indicators of treatment responsiveness to rituximab and plasmapheresis in antibody-mediated rejection after kidney transplantation.
    Immenschuh S, Zilian E, Dämmrich ME, Schwarz A, Gwinner W, Becker JU, Blume CA.
    Transplantation; 2015 Jan; 99(1):56-62. PubMed ID: 25121474
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.